1
|
Meanwell NA. The pyridazine heterocycle in molecular recognition and drug discovery. Med Chem Res 2023; 32:1-69. [PMID: 37362319 PMCID: PMC10015555 DOI: 10.1007/s00044-023-03035-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Accepted: 02/06/2023] [Indexed: 03/17/2023]
Abstract
The pyridazine ring is endowed with unique physicochemical properties, characterized by weak basicity, a high dipole moment that subtends π-π stacking interactions and robust, dual hydrogen-bonding capacity that can be of importance in drug-target interactions. These properties contribute to unique applications in molecular recognition while the inherent polarity, low cytochrome P450 inhibitory effects and potential to reduce interaction of a molecule with the cardiac hERG potassium channel add additional value in drug discovery and development. The recent approvals of the gonadotropin-releasing hormone receptor antagonist relugolix (24) and the allosteric tyrosine kinase 2 inhibitor deucravacitinib (25) represent the first examples of FDA-approved drugs that incorporate a pyridazine ring. In this review, the properties of the pyridazine ring are summarized in comparison to the other azines and its potential in drug discovery is illustrated through vignettes that explore applications that take advantage of the inherent physicochemical properties as an approach to solving challenges associated with candidate optimization. Graphical Abstract
Collapse
|
2
|
Chen L, Liu Z, Li X. Recent Advances in Dual BRD4-Kinase Inhibitors Base on Polypharmacology. ChemMedChem 2022; 17:e202100731. [PMID: 35146935 DOI: 10.1002/cmdc.202100731] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Revised: 02/08/2022] [Indexed: 11/11/2022]
Abstract
Epigenetic reader BRD4 is involved in chromatin remodeling and transcriptional regulation, making it a promising therapeutic target. However, during the past decades, the results of many BRD4 inhibitors that have entered clinical trials were, in the main, unsatisfactory, due to some therapeutic limitations such as off-target effects and drug resistance. Combining a BRD4 inhibitor with another drug was expected to be an ideal option to overcome these "bottlenecks" and achieve improved therapeutic outcomes. However, combination therapy might trigger toxicity caused by drug-drug interaction, complex pharmacokinetic and additive effects. Recently, the application of dual-target drugs targeting BRD4 and other kinases has emerged to be an attractive approach to remedy defects of a single BRD4 inhibitor. Herein, this review focuses on recent advances in the discovery of dual BRD4-kinase inhibitors, with emphasis on their co-crystal structures and structure-activity relationships (SARs), as well as perspective prospects in the field.
Collapse
Affiliation(s)
- Li Chen
- Shandong University Cheeloo College of Medicine, Medicinal chemistry, West Wenhua Road 44, 250012, Jinnan, CHINA
| | - Zhaopeng Liu
- Institute of Medicinal Chemistry, Department of Organic Chemistry, School of Pharmaceutical Sciences, Shandong Un, No.44 WhenHua XiLu, 250012, Jinan, CHINA
| | - Xun Li
- Shandong First Medical University, Institute of Materia Medica, CHINA
| |
Collapse
|
3
|
Srilaxmi D, Sreenivasulu R, Mak KK, Pichika MR, Jadav SS, Ahsan MJ, Rao MVB. Design, synthesis, anticancer evaluation and molecular docking studies of chalcone linked pyrido[4,3-b]pyrazin-5(6H)-one derivatives. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2020.129851] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. ADVANCES IN HETEROCYCLIC CHEMISTRY 2017. [DOI: 10.1016/bs.aihch.2016.11.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
5
|
Liu W, Chen C, Tan L. Synthesis of Multisubstituted Pyridin-2(3H)-ones via Nickel-Catalyzed Intermolecular Condensation of β-Ketobutylanilides. ChemistrySelect 2016. [DOI: 10.1002/slct.201600235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Weibing Liu
- College of Chemical Engineering; Guangdong University of Petrochemical Technology; 2 Guandu Road Maoming 525000, P. R. China
| | - Cui Chen
- College of Chemical Engineering; Guangdong University of Petrochemical Technology; 2 Guandu Road Maoming 525000, P. R. China
| | - Liquan Tan
- College of Chemical Engineering; Guangdong University of Petrochemical Technology; 2 Guandu Road Maoming 525000, P. R. China
| |
Collapse
|
6
|
Iodine catalyzed simple and efficient synthesis of antiproliferative 2-pyridones. Bioorg Med Chem Lett 2016; 26:2159-63. [DOI: 10.1016/j.bmcl.2016.03.071] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Revised: 02/25/2016] [Accepted: 03/17/2016] [Indexed: 11/23/2022]
|
7
|
Kusakabe KI, Ide N, Daigo Y, Itoh T, Yamamoto T, Kojima E, Mitsuoka Y, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Yoshizawa H, Murai H, Nakamura Y. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. Bioorg Med Chem 2015; 23:2247-60. [PMID: 25801152 DOI: 10.1016/j.bmc.2015.02.042] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Revised: 02/17/2015] [Accepted: 02/18/2015] [Indexed: 01/15/2023]
Abstract
Mps1, also known as TTK, is a dual-specificity kinase that regulates the spindle assembly check point. Increased expression levels of Mps1 are observed in cancer cells, and the expression levels correlate well with tumor grade. Such evidence points to selective inhibition of Mps1 as an attractive strategy for cancer therapeutics. Starting from an aminopyridine-based lead 3a that binds to a flipped-peptide conformation at the hinge region in Mps1, elaboration of the aminopyridine scaffold at the 2- and 6-positions led to the discovery of 19c that exhibited no significant inhibition for 287 kinases as well as improved cellular Mps1 and antiproliferative activities in A549 lung carcinoma cells (cellular Mps1 IC₅₀=5.3 nM, A549 IC₅₀=26 nM). A clear correlation between cellular Mps1 and antiproliferative IC₅₀ values indicated that the antiproliferative activity observed in A549 cells would be responsible for the cellular inhibition of Mps1. The X-ray structure of 19c in complex with Mps1 revealed that this compound retains the ability to bind to the peptide flip conformation. Finally, comparative analysis of the X-ray structures of 19c, a deamino analogue 33, and a known Mps1 inhibitor bound to Mps1 provided insights into the unique binding mode at the hinge region.
Collapse
Affiliation(s)
- Ken-ichi Kusakabe
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
| | - Nobuyuki Ide
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yataro Daigo
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan; Department of Medical Oncology, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan
| | - Takeshi Itoh
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Takahiko Yamamoto
- Innovative Drug Discovery Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Eiichi Kojima
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yasunori Mitsuoka
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Genta Tadano
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Sachie Tagashira
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Kenichi Higashino
- Innovative Drug Discovery Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yousuke Okano
- Innovative Drug Discovery Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yuji Sato
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Makiko Inoue
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Motofumi Iguchi
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Takayuki Kanazawa
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yukichi Ishioka
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Keiji Dohi
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yasuto Kido
- Drug Developmental Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Shingo Sakamoto
- Drug Developmental Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Shigeru Ando
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Masahiro Maeda
- Innovative Drug Discovery Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Masayo Higaki
- Innovative Drug Discovery Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Hidenori Yoshizawa
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Hitoshi Murai
- Medicinal Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
| | - Yusuke Nakamura
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| |
Collapse
|
8
|
Apsunde T, Wurz RP. Pyridin-2-one Synthesis Using Ester Enolates and Aryl Aminoaldehydes and Ketones. J Org Chem 2014; 79:3260-6. [DOI: 10.1021/jo500284n] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- Tushar Apsunde
- Department
of Chemistry, University of New Orleans, 2000 Lakeshore Drive, New Orleans, Louisiana 70148, United States
| | - Ryan P. Wurz
- Therapeutic Discovery, Amgen Inc., One Amgen
Center Drive, Thousand Oaks, California 91320-1799, United States
| |
Collapse
|
9
|
Montoir D, Tonnerre A, Duflos M, Bazin MA. Differential Functionalization of 1,6-Naphthyridin-2(1H)-ones through Sequential One-Pot Suzuki-Miyaura Cross-Couplings. European J Org Chem 2014. [DOI: 10.1002/ejoc.201301631] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
10
|
Shu L, Wang P, Gu C, Garofalo L, Alabanza LM, Dong Y. A Concise Synthesis of a Tetrahydropyrazolopyrazine Building Block. Org Process Res Dev 2012. [DOI: 10.1021/op300270r] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Lianhe Shu
- Process Research
and Synthesis, Pharma Early Research and Development (pRED), Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley,
New Jersey 07110, United States
| | - Ping Wang
- Process Research
and Synthesis, Pharma Early Research and Development (pRED), Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley,
New Jersey 07110, United States
| | - Chen Gu
- Process Research
and Synthesis, Pharma Early Research and Development (pRED), Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley,
New Jersey 07110, United States
| | - Lisa Garofalo
- Process Research
and Synthesis, Pharma Early Research and Development (pRED), Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley,
New Jersey 07110, United States
| | - Lady Mae Alabanza
- Process Research
and Synthesis, Pharma Early Research and Development (pRED), Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley,
New Jersey 07110, United States
| | - Yan Dong
- Process Research
and Synthesis, Pharma Early Research and Development (pRED), Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley,
New Jersey 07110, United States
| |
Collapse
|
11
|
Kusakabe KI, Ide N, Daigo Y, Itoh T, Higashino K, Okano Y, Tadano G, Tachibana Y, Sato Y, Inoue M, Wada T, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Tagashira S, Kido Y, Sakamoto S, Yasuo K, Maeda M, Yamamoto T, Higaki M, Endoh T, Ueda K, Shiota T, Murai H, Nakamura Y. Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation. ACS Med Chem Lett 2012; 3:560-4. [PMID: 24900510 DOI: 10.1021/ml3000879] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2012] [Accepted: 06/06/2012] [Indexed: 11/30/2022] Open
Abstract
Monopolar spindle 1 (Mps1) is an attractive cancer drug target due to the important role that it plays in centrosome duplication, the spindle assembly checkpoint, and the maintenance of chromosomal stability. A design based on JNK inhibitors with an aminopyridine scaffold and subsequent modifications identified diaminopyridine 9 with an IC50 of 37 nM. The X-ray structure of 9 revealed that the Cys604 carbonyl group of the hinge region flips to form a hydrogen bond with the aniline NH group in 9. Further optimization of 9 led to 12 with improved cellular activity, suitable pharmacokinetic profiles, and good in vivo efficacy in the mouse A549 xenograft model. Moreover, 12 displayed excellent selectivity over 95 kinases, indicating the contribution of its unusual flipped-peptide conformation to its selectivity.
Collapse
Affiliation(s)
- Ken-ichi Kusakabe
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Nobuyuki Ide
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yataro Daigo
- Laboratory of Molecular
Medicine,
Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,
Tokyo 108-8639, Japan
- Department
of Medical Oncology, Shiga University of Medical Science, Seta Tsukinowa-cho,
Otsu, Shiga 520-2192, Japan
| | - Takeshi Itoh
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Kenichi Higashino
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yousuke Okano
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Genta Tadano
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yuki Tachibana
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yuji Sato
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Makiko Inoue
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Tooru Wada
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Motofumi Iguchi
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Takayuki Kanazawa
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yukichi Ishioka
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Keiji Dohi
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Sachie Tagashira
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yasuto Kido
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Shingo Sakamoto
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Kazuya Yasuo
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Masahiro Maeda
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Takahiko Yamamoto
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Masayo Higaki
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Takeshi Endoh
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Kazuo Ueda
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Takeshi Shiota
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Hitoshi Murai
- Medicinal Research Laboratories,
Drug Developmental Research Laboratories, and Innovative Drug Discovery
Research Laboratories, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825,
Japan
| | - Yusuke Nakamura
- Laboratory of Molecular
Medicine,
Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,
Tokyo 108-8639, Japan
| |
Collapse
|
12
|
Brown DS, Cumming JG, Bethel P, Finlayson J, Gerhardt S, Nash I, Pauptit RA, Pike KG, Reid A, Snelson W, Swallow S, Thompson C. The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. Bioorg Med Chem Lett 2012; 22:3879-83. [DOI: 10.1016/j.bmcl.2012.04.116] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 04/25/2012] [Accepted: 04/27/2012] [Indexed: 11/27/2022]
|
13
|
Vinh NB, Simpson JS, Scammells PJ, Chalmers DK. Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK. J Comput Aided Mol Des 2012; 26:409-23. [PMID: 22527960 DOI: 10.1007/s10822-012-9569-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2011] [Accepted: 03/26/2012] [Indexed: 12/25/2022]
Abstract
We have used virtual screening to develop models for the binding of aryl substituted heterocycles to p38α MAPK. Virtual screening was conducted on a number of p38α MAPK crystal structures using a library of 46 known p38α MAPK inhibitors containing a heterocyclic core substituted by pyridine and fluorophenyl rings (structurally related to SB203580) and a set of decoy compounds. Multiple protonation states and tautomers of active and decoy compounds were considered. Each docking model was evaluated using receiver operating characteristic (ROC) curves and enrichment factors. The two best performing single crystal structures were found to be 1BL7 and 2EWA, with enrichment factors of 14.1 and 13.0 at 2% of the virtual screen respectively. Ensembles of up to four receptors of similar conformations were generated, generally giving good or very good performances with high ROC AUCs and good enrichment. The 1BL7-2EWA ensemble was able to outperform each of its constituent receptors and gave high enrichment factors of 17.3, 12.0, 8.0 at 2, 5 and 10% respectively, of the virtual screen. A ROC AUC of 0.94 was obtained for this ensemble. This method may be applied to other proteins where there are a large number of inhibitor classes with different binding site conformations.
Collapse
Affiliation(s)
- Natalie B Vinh
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), 381 Royal Parade, Parkville, VIC, 3052, Australia
| | | | | | | |
Collapse
|
14
|
Nakayama H, Ishihara K, Akiba S, Uenishi J. Synthesis of N-[2-(2,4-Difluorophenoxy)trifluoromethyl-3-pyridyl]sulfonamides and their inhibitory activities against secretory phospholipase A₂. Chem Pharm Bull (Tokyo) 2011; 59:1069-72. [PMID: 21804258 DOI: 10.1248/cpb.59.1069] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
N-[2-(2,4-Difluorophenoxy)trifluoromethyl-3-pyridyl]sulfonamide derivatives 3-6 were prepared by the reaction of 3-pyridylamines and sulfonyl chlorides. Inhibitory activities of these compounds toward secretory phospholipase A₂ (sPLA₂) were examined and N-[2-(2,4-difluorophenoxy)-5-trifluoromethyl-3-pyridyl]-2-naphthalenesulfonamide (5c) was found to be the most potent against sPLA₂ with an IC₅₀ value of 90 µM.
Collapse
Affiliation(s)
- Hitoshi Nakayama
- Department of Pharmaceutical Chemistry, Kyoto Pharmaceutical University, Japan.
| | | | | | | |
Collapse
|
15
|
Meanwell NA. Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design. J Med Chem 2011; 54:2529-91. [DOI: 10.1021/jm1013693] [Citation(s) in RCA: 1876] [Impact Index Per Article: 144.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Nicholas A. Meanwell
- Department of Medicinal Chemistry, Bristol-Myers Squibb Pharmaceutical Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| |
Collapse
|
16
|
Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis. Future Med Chem 2011; 3:309-37. [DOI: 10.4155/fmc.10.294] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Aberrant kinase signaling leads to a multitude of disease states. The clinical and commercial success of agents typified by imatinib or dasatinib in the treatment of hematological malignancies has further validated kinase inhibition as a useful clinical strategy. This increased interest in kinases as therapeutic targets is evidenced by the rapidly increasing number of patent applications and peer-reviewed articles. This article discusses recent Patent that describe small molecules targeting the DFG-in active kinase conformation, by the so-called ‘Type I½’ inhibitor, against a small set of clinically relevant targets such as B-Raf, p38α, Jak2 and EphB4. Preclinical and clinical data are also highlighted for the most promising new molecular entities.
Collapse
|
17
|
Qian W, Winternheimer D, Allen J. A “Click and Activate” Approach in One-Pot Synthesis of a Triazolyl-Pyridazinone Library. Org Lett 2011; 13:1682-5. [DOI: 10.1021/ol200183b] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Wenyuan Qian
- Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - David Winternheimer
- Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Jennifer Allen
- Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| |
Collapse
|